Trial · NCT03296163
Adverse events232
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 232
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Alopecia | Skin and subcutaneous tissue disorders | MB02 (Bevacizumab Biosimilar Drug) | 155 | 311 | |
| other | Alopecia | Skin and subcutaneous tissue disorders | EU-approved Avastin® | 163 | 310 | |
| other | Anemia | Blood and lymphatic system disorders | MB02 (Bevacizumab Biosimilar Drug) | 101 | 311 | |
| other | Anemia | Blood and lymphatic system disorders | EU-approved Avastin® | 94 | 310 | |
| other | Thrombocytopenia | Blood and lymphatic system disorders | MB02 (Bevacizumab Biosimilar Drug) | 41 | 311 | |
| other | Thrombocytopenia | Blood and lymphatic system disorders | EU-approved Avastin® | 42 | 310 | |
| other | Neutropenia | Blood and lymphatic system disorders | MB02 (Bevacizumab Biosimilar Drug) | 34 | 311 | |
| other | Neutropenia | Blood and lymphatic system disorders | EU-approved Avastin® | 45 | 310 | |
| other | Leukopenia | Blood and lymphatic system disorders | MB02 (Bevacizumab Biosimilar Drug) | 24 | 311 | |
| other | Leukopenia | Blood and lymphatic system disorders | EU-approved Avastin® | 18 | 310 | |
| other | Neuropathy peripheral | Nervous system disorders | MB02 (Bevacizumab Biosimilar Drug) | 38 | 311 | |
| other | Neuropathy peripheral | Nervous system disorders | EU-approved Avastin® | 41 | 310 | |
| other | Peripheral sensory neuropathy | Nervous system disorders | MB02 (Bevacizumab Biosimilar Drug) | 22 | 311 | |
| other | Peripheral sensory neuropathy | Nervous system disorders | EU-approved Avastin® | 23 | 310 | |
| other | Paresthesia | Nervous system disorders | MB02 (Bevacizumab Biosimilar Drug) | 21 | 311 | |
| other | Paresthesia | Nervous system disorders | EU-approved Avastin® | 13 | 310 | |
| other | Fatigue | General disorders | MB02 (Bevacizumab Biosimilar Drug) | 39 | 311 | |
| other | Fatigue | General disorders | EU-approved Avastin® | 36 | 310 | |
| other | Asthenia | General disorders | MB02 (Bevacizumab Biosimilar Drug) | 39 | 311 | |
| other | Asthenia | General disorders | EU-approved Avastin® | 29 | 310 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03296163/events